Video Experimental Relacionado

Updated: Jan 13, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Comparación de la eficacia de la terapia neoadyuvante del cáncer de mama triple negativo: un análisis de

Yicheng Jiang¹, Jiajia Zeng¹, Jian Liu²

¹Department of Breast Surgery, Guilin Municipal Hospital of Traditional Chinese Medicine, Guilin, China.

|January 10, 2026

Abstracto

Background:

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis and limited treatment options. Currently, nonmetastatic TNBC is mostly treated with neoadjuvant chemotherapy, but comparisons between these neoadjuvant regimens are dearth.

Methods:

PubMed, Embase, Medline, Cochrane Library, Web of ClinicalTrials.gov, and major international conference databases were systematically searched for randomized controlled trials (RCTs) on the efficacy of various neoadjuvant chemotherapy treatments in patients with TNBC from inception to January 2025. The primary research endpoint was the pathological complete response (pCR) rate. The secondary endpoint was the odds ratios (ORs) at different time points of event-free survival (EFS) and overall survival (OS). The tertiary endpoints were the hazard ratios (HRs) of EFS and OS compared by Bayesian network meta-analysis, as well as corresponding Bayesian network meta-regression analysis with the median follow-up time as the covariate. The above processes were conducted by RStudio 4.2.2 orchestrated with STATA 17.0 MP.

Results:

For the primary endpoint, compared to regimens containing anthracycline and taxanes (AT), regimens containing anthracycline, taxanes, platinum, and programmed cell death protein-1 (ATPtPD1) showed significant higher pCR rate (OR = 5.68). For the secondary endpoint, compared to AT, ATPtPD1 showed significant longer EFS/OS. For EFS: OR = 2.28 at 18th month; OR = 2.43 at 24th month; OR = 3.21 at 30th month; OR = 4.23 at 36th month; OR = 4.62 at 42nd month; OR = 4.04 at 48th month. For OS: OR = 3.56 at 18th month; OR = 2.23 at 24th month; OR = 2.49 at 30th month; OR = 2.49 at 36th month; OR = 3.17 at 42nd month; OR = 2.97 at 48th month. For the tertiary endpoints, for HR of EFS, compared to AT, ATPtPD1 indicated significant advantage (HR = 2.24, 95% confidence interval [CI]: 1.42-3.59), after meta-regression analysis, shows advantages as well (HR = 2.29, 95% CI: 1.39-3.89). For HR of OS, compared to AT, ATPtPD1 indicated significant advantage (HR = 2.67, 95% CI: 1.03-7.35), after meta-regression analysis, shows advantages as well (HR = 2.70, 95% CI: 1.18-6.33).

Conclusions:

Considering efficacy on pCR and OS/EFS together, ATPtPD1 should be considered as the best recommendation in neoadjuvant therapies of TNBC.

Palabras clave:

metaanálisis de red bayesiano quimioterapia inhibidor de puntos de control inmunitario tratamiento neoadyuvante análisis de meta-regresión de red cáncer de mama triple negativo

Más Videos Relacionados

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Videos de Conceptos Relacionados

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...